U.S. Next Generation Sequencing Market To Reach $11.82 Billion By 2030

U.S. Next Generation Sequencing Market Growth & Trends

The U.S. next generation sequencing market size is anticipated to reach USD 11.82 billion by 2030, expanding at a CAGR of 20.14% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing applications of next generation sequencing (NGS) in drug discovery, diagnostics, and personalized medicine, as well as the growing prevalence of cancer and other genetic disorders. In addition, rising cardiovascular diseases is another factor driving the U.S. market’s growth.

According to Centers for Disease Control and Prevention (CDC), heart disease remains the leading cause of death across various demographics in the U.S., including men, women, and individuals of most racial and ethnic backgrounds. On average, a person dies of cardiovascular disease every 33 seconds in the U.S. Sequencing can be employed in cardiovascular genetics to identify genetic risk factors for conditions like familial hypercholesterolemia, cardiomyopathies, and arrhythmias. It enables early detection of individuals at risk and facilitates personalized treatment plans.

Continuous innovations and improvements in NGS technologies, such as sequencing platforms, bioinformatics tools, and sample preparation methods, drive market growth. Enhanced sequencing speed, accuracy, and cost-effectiveness make NGS more accessible and applicable across diverse research and clinical applications. The expanding utility of sequencing techniques in clinical diagnostics, including oncology, rare diseases, genetic disorders, and infectious diseases, is a significant driver of market growth. NGS enables precise and comprehensive genetic analysis, leading to improved diagnosis, treatment selection, and patient care.

The COVID-19 pandemic has significantly affected the U.S. NGS market. As healthcare providers focus on managing the pandemic, routine medical procedures, including genetic testing, have been postponed or canceled. This has caused a decline in the demand for NGS tests in the country. However, the pandemic has also highlighted the importance of genetic testing and its potential in managing and treating diseases. As a result, there has been a renewed interest in NGS-based research and development, which is expected to drive the market’s growth in the coming years. Furthermore, the increased demand for COVID-19 testing has led to the development of new NGS-based diagnostic tests. These tests are expected to play a crucial role in the early detection and management of the disease.

The U.S. NGS market’s growth is driven by the substantial cost associated with NGS technologies. The initial investment in sequencing instruments, reagents, and infrastructure can be prohibitively high for many research laboratories, academic institutions, and smaller healthcare facilities. Additionally, the ongoing operational expenses and maintenance costs further strain limited budgets, hindering access to NGS technology. Sequencing generates vast amounts of complex data, posing significant challenges in storage, analysis, and interpretation. Managing terabytes to petabytes of sequencing data requires robust computational resources and sophisticated bioinformatics tools. Moreover, ensuring data integrity, security, and compliance with privacy regulations adds another layer of complexity to NGS data management.

 Request a free sample copy or view report summary: U.S. Next Generation Sequencing Market Report

U.S. Next Generation Sequencing (NGS) Market Report Highlights

• Consumables dominated the product segment in 2023 owing to the increasing demand for high-quality and reliable sequencing products

• The oncology application segment held the largest revenue share of 26.67% in 2023. On the other hand, the consumer genomics segment is expected to grow at the highest CAGR by 2030.

• In 2023, targeted sequencing & resequencing dominated the technology segment with a revenue share of 71.14% and is expected to grow at the highest CAGR by 2030

• In 2023, sequencing dominated the workflow segment with a share of 57.60% while NGS data analysis is expected to grow at the highest CAGR from 2024 to 2030

• Academic research dominated the end-use segment with a revenue share of 50.49% in 2023

U.S. Next Generation Sequencing (NGS) Market Segmentation

Grand View Research has segmented the U.S. next generation sequencing market based on product, technology, workflow, application, and end-use:

U.S. Next Generation Sequencing (NGS) Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Whole Genome Sequencing

• Whole Exome Sequencing

• Targeted Sequencing & Resequencing

  • DNA-based

  • RNA-based

• Others

U.S. Next Generation Sequencing (NGS) Product Outlook (Revenue, USD Million, 2018 - 2030)

• Platforms

  • Sequencing

  • Data Analysis

• Consumables

  • Sample Preparation

  • Target Enrichment

  • Others

U.S. Next Generation Sequencing (NGS) Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

  • Diagnostics and Screening

    • Oncology Screening

      • Sporadic Cancer

      • Inherited Cancer

    • Companion Diagnostics

    • Other Diagnostics

  • Research Studies

• Clinical Investigation

  • Infectious Diseases

  • Inherited Diseases

  • Idiopathic Diseases

  • Non-Communicable/Other Diseases

• Reproductive Health

  • NIPT

    • Aneuploidy

    • Microdeletions

  • PGT

  • Newborn Genetic Screening

  • Single Gene Analysis

• HLA Typing/Immune System Monitoring

• Metagenomics, Epidemiology & Drug Development

• Agrigenomics & Forensics

• Consumer Genomics

U.S. Next Generation Sequencing (NGS) Workflow Outlook (Revenue, USD Million, 2018 - 2030)

• Pre-sequencing

  • Library Preparation

    • NGS Library Preparation Kits

    • Semi-automated Library Preparation

    • Automated Library Preparation

  • Others

• Sequencing

• NGS Data Analysis

  • NGS Primary Data Analysis

  • NGS Secondary Data Analysis

  • NGS Tertiary Data Analysis

U.S. Next Generation Sequencing (NGS) End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Academic Research

• Clinical Research

• Hospitals & Clinics

• Pharma & Biotech Entities

• Other Users

List of Key Players in the U.S. Next Generation Sequencing (NGS) Market

• Illumina, Inc.

• QIAGEN

• Thermo Fisher Scientific, Inc.

• BGI

• Pacific Biosciences

• Bio Rad Laboratories

• Oxford Nanopore Technologies, Inc.

• F. Hoffmann-La Roche AG

• Agilent Technologies, Inc.

• Eurofins Scientific